ESMO 2025 – Boehringer and Bayer eye the front line
Boehringer’s Hernexeos and Bayer’s sevabertinib look similar in first-line HER2-mutant NSCLC.
Boehringer goes earlier than Bayer
A phase 3 trial of Hernexeos in adjuvant HER2m NSCLC is planned.
FDA red and green lights: August 2025
Boehringer’s Hernexeos beats Bayer’s sevabertinib to the US.
BeOne cashes in its Imdelltra royalty
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
The month ahead: August’s upcoming events
Jazz’s Chimerix buy faces its big test.
Boehringer slims down in SIRPα
The group has canned its first-generation project, hoping that a follow-on will reach more patients.
Takeda says no to B7-H3
TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.
AACR 2025 – Boehringer still has broad zongertinib hopes
Data in HER2-mutated NSCLC still look good, and studies in HER2-amplified tumours continue.
Another false dawn for p53
Boehringer discontinues brigimadlin while others continue to struggle.
Oric looks over its shoulder
Tough equity markets as well as competitor developments prompt a narrowed focus.
